Cargando…

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification

Detalles Bibliográficos
Autores principales:	Hotson, Drew, Alvarado, Ryan, Conroy, Andrew, Putta, Santosh, Simeone, Ester, Esposito, Assunta, Capone, Mariaelena, Madonna, Gabriele, Grimaldi, Antonio M, Rosen, David, Liang, Spencer, Cesano, Alessandra, Ascierto, Paolo A, Hawtin, Rachael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991189/ http://dx.doi.org/10.1186/2051-1426-1-S1-P257

Ejemplares similares

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2014)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
por: Mozzillo, Nicola, et al.
Publicado: (2015)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
por: Simeone, Ester, et al.
Publicado: (2014)

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters
por: Simeone, Ester, et al.
Publicado: (2014)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Immune monitoring technology primer: Single Cell Network Profiling (SCNP)
por: Hawtin, Rachael E., et al.
Publicado: (2015)

Functional Pathway Analysis Using SCNP of FLT3 Receptor Pathway Deregulation in AML Provides Prognostic Information Independent from Mutational Status
por: Cesano, Alessandra, et al.
Publicado: (2013)

Ipilimumab and Stereotactic Radiosurgery with CyberKnife(®) System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
por: Borzillo, Valentina, et al.
Publicado: (2021)

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
por: Rosen, David B., et al.
Publicado: (2013)

Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP)
por: Rosen, David B, et al.
Publicado: (2014)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Peripheral blood mononuclear cells (PBMC) microbiome is not affected by colon microbiota in healthy goats
por: Peña-Cearra, Ainize, et al.
Publicado: (2021)

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
por: Capone, Mariaelena, et al.
Publicado: (2020)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
por: Madonna, Gabriele, et al.
Publicado: (2021)

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
por: Atripaldi, Luigi, et al.
Publicado: (2021)

HCG-Activated Human Peripheral Blood Mononuclear Cells (PBMC) Promote Trophoblast Cell Invasion
por: Yu, Nan, et al.
Publicado: (2015)

Free fatty acids and peripheral blood mononuclear cells (PBMC) are correlated with chronic inflammation in obesity
por: Liqiang, Su, et al.
Publicado: (2023)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Gene expression of inflammasome components in peripheral blood mononuclear cells (PBMC) of vascular patients increases with age
por: Wu, Xiaoyu, et al.
Publicado: (2015)

Overexpression of miR-31 in Peripheral Blood Mononuclear Cells (PBMC) from Patients with Ankylosing Spondylitis
por: Wang, Mengmeng, et al.
Publicado: (2017)

In Vitro Response of Human Peripheral Blood Mononuclear Cells (PBMC) to Collagen Films Treated with Cold Plasma
por: Chen, Rui, et al.
Publicado: (2017)

Evaluation of expression of common genes in the intestine and peripheral blood mononuclear cells (PBMC) associated with celiac disease
por: Khalkhal, Ensieh, et al.
Publicado: (2020)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps
por: Modestino, Luca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ortoedsa9fukqf06vf67bhkk1h